Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study-Reference-Cited by-同舟云学术

Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study

Published:2009-12 Issue:6 Volume:68 Page:948-955
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Beghetti Maurice,Haworth Sheila G.,Bonnet Damien,Barst Robyn J.,Acar Philippe,Fraisse Alain,Ivy Dunbar D.,Jais Xavier,Schulze-Neick Ingram,GaliÃ¨ Nazzareno,Morganti Adele,Dingemanse Jasper,Kusic-Pajic Andjela,Berger Rolf M. F.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.2009.03532.x/fullpdf

Reference22 articles.

1. Primary pulmonary hypertension;Rubin;N Engl J Med,1997

2. Pulmonary arterial hypertension;Farber;N Engl J Med,2004

3. The management of pulmonary hypertension in children;Haworth;Arch Dis Child,2008

4. Pulmonary arterial hypertension in children: a medical update;Rosenzweig;Curr Opin Pediatr,2008

5. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry;Alonzo;Ann Intern Med,1991

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Sequelae of Bronchopulmonary Dysplasia in Preterm Neonates Born before 32 Weeks of Gestational Age: Impact of Associated Pulmonary and Systemic Hypertension;Journal of Cardiovascular Development and Disease;2024-07-26

2. Neue Aspekte bei der pulmonalen Hypertonie im Kindesalter – kommentierte 2022ERS/ESC-PH-Guidelines;Pneumologie;2023-11

3. Pediatric Population Pharmacokinetic Modeling and Exposure–Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data;The Journal of Clinical Pharmacology;2023-01-29

4. Antihypertensive Drugs for Pulmonary Hypertension, Cardiovascular Drugs for Right and Left Ventricular Failure;Noninvasive Ventilation. The Essentials;2023

5. Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension;Pediatric Pulmonology;2022-12-28